TruPress
Procerus Enterprises · Decision date Sep 10, 2026
What did the FDA decide?
FDA recorded a substantial equivalence (SESE) decision for K254074, TruPress, on 2026-09-10. The applicant of record is Procerus Enterprises, and the product is classified under product code DRS, described in the FDA listing as a transducer for extravascular blood-pressure measurement, within the Cardiovascular specialty. A SESE decision indicates clearance of the 510(k) submission; it is not premarket approval of a new device system.
The source record does not state the predicate device, the specific component or change under review, or any indications for use, and the linked FDA excerpt does not supply them. The excerpt also lists Ontogen Medtech and a Salt Lake City address alongside the applicant, but the record does not explain that relationship. Whether the submission covered a new transducer or a modification to an existing one therefore remains unknown from the available data.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 10, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254074
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Procerus Enterprises
- Product code
- DRS
- Decision code
- SESE
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transducer, Blood-Pressure, Extravascular.
- Applicant
- Procerus Enterprises
- Product code
- DRS
- FDA device class
- 2
FDA decision timeline
K254074 received
Application receipt date recorded by FDA.
K254074 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Procerus Enterprises
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Salt Lake City, UT
Sources and methodology
- Original FDA record: K254074
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records